Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Burden of albinism: development and validation of a burden assessment tool

Authors: Fanny Morice-Picard, Charles Taïeb, Aurelie Marti, Antoine Gliksohn, Mohammed Bennani, Christine Bodemer, Khaled Ezzedine, Filière Maladies Rares en Dermatologie: FIMARAD

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

Albinism comprises a group of autosomal recessive diseases that are characterized by poor vision and a variable hypopigmentation phenotype. A comprehensive literature review showed that no tool can assess the burden experienced by individuals who present with albinism, although such a tool is needed and would be beneficial for clinicians and patients alike.

Method

The questionnaire was devised using standardized methodology for developing and validating questionnaires on the quality of life of subjects according to the following chronological structure: conceptual phase, development phase, and then validation phase. A multidisciplinary working group was assembled, including experts on questionnaire design and development, dermatologists specializing in care for patients with albinism, and representatives of the Genespoir association.

Results

Based on an initial verbatim report, the workgroup compiled a list of items that were transcribed and reformulated into questions. During the validation phase, principal component analysis (PCA) was conducted on the 24 items, which allowed the questionnaire to be reduced to 20 questions [Q]. The standardized regression coefficients were all greater than 0.5 for their corresponding factors. Based on their normalized regression coefficients, each group of questions was linked to one of the following four dimensions, with each dimension consisting of at least three questions: “Live with” (8 Q), “Daily life” (3 Q), “Resignation” (3 Q), and “Fear of the future” (6 Q). All dimensions correlated well with the overall BoA score. Cronbach’s α was 0.92 for the entire BoA scale, confirming excellent internal coherence. Intradimensional coherences all demonstrated excellent reliability (α > 0.65). The BoA questionnaire was highly correlated with the SF12, RSES and DLQI validated questionnaires. This outcome confirmed the external validity.

Conclusion

This questionnaire represents the first specific assessment tool for evaluating the burden of albinism. It is easy to use and relatively quick to complete, which will allow the burden to be evaluated over time with a reproducible questionnaire. To ensure that this questionnaire can be used by as many people as possible, cultural and linguistic validation in US English was conducted with the original French version.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gargiulo A, Testa F, Rossi S, Di Iorio V, Fecarotta S, de Berardinis T, et al. Molecular and clinical characterization of albinism in a large cohort of Italian patients. Invest Ophthalmol Vis Sci. 2011;52(3):1281–9.CrossRef Gargiulo A, Testa F, Rossi S, Di Iorio V, Fecarotta S, de Berardinis T, et al. Molecular and clinical characterization of albinism in a large cohort of Italian patients. Invest Ophthalmol Vis Sci. 2011;52(3):1281–9.CrossRef
2.
go back to reference Grønskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K, et al. Birth prevalence and mutation spectrum in danish patients with autosomal recessive albinism. Invest Ophthalmol Vis Sci. 2009;50(3):1058–64.CrossRef Grønskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K, et al. Birth prevalence and mutation spectrum in danish patients with autosomal recessive albinism. Invest Ophthalmol Vis Sci. 2009;50(3):1058–64.CrossRef
3.
go back to reference Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43.CrossRef Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43.CrossRef
4.
go back to reference Hutton SM, Spritz RA. Comprehensive analysis of oculocutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type. J Investig Dermatol. 2008;128(10):2442–50.CrossRef Hutton SM, Spritz RA. Comprehensive analysis of oculocutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type. J Investig Dermatol. 2008;128(10):2442–50.CrossRef
5.
go back to reference Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99–115.CrossRef Oetting WS, King RA. Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum Mutat. 1999;13(2):99–115.CrossRef
6.
go back to reference Rundshagen U, Zühlke C, Opitz S, Schwinger E, Käsmann-Kellner B. Mutations in the MATP gene in five German patients affected by oculocutaneous albinism type 4. Hum Mutat. 2004;23(2):106–10.CrossRef Rundshagen U, Zühlke C, Opitz S, Schwinger E, Käsmann-Kellner B. Mutations in the MATP gene in five German patients affected by oculocutaneous albinism type 4. Hum Mutat. 2004;23(2):106–10.CrossRef
7.
go back to reference Rooryck C, Morice-Picard F, Elçioglu NH, Lacombe D, Taieb A, Arveiler B. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res. 2008;21(5):583–7.CrossRef Rooryck C, Morice-Picard F, Elçioglu NH, Lacombe D, Taieb A, Arveiler B. Molecular diagnosis of oculocutaneous albinism: new mutations in the OCA1-4 genes and practical aspects. Pigment Cell Melanoma Res. 2008;21(5):583–7.CrossRef
8.
go back to reference Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J, et al. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet. 2004;74(3):466–71.CrossRef Inagaki K, Suzuki T, Shimizu H, Ishii N, Umezawa Y, Tada J, et al. Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. Am J Hum Genet. 2004;74(3):466–71.CrossRef
9.
go back to reference Lin S-Y, Chien S-C, Su Y-N, Lee C-N, Chen C-P. Rapid genetic analysis of oculocutaneous albinism (OCA1) using denaturing high performance liquid chromatography (DHPLC) system. Prenat Diagn. 2006;26(5):466–70.CrossRef Lin S-Y, Chien S-C, Su Y-N, Lee C-N, Chen C-P. Rapid genetic analysis of oculocutaneous albinism (OCA1) using denaturing high performance liquid chromatography (DHPLC) system. Prenat Diagn. 2006;26(5):466–70.CrossRef
10.
go back to reference Suzuki T, Tomita Y. Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4. J Dermatol Sci. 2008;51(1):1–9.CrossRef Suzuki T, Tomita Y. Recent advances in genetic analyses of oculocutaneous albinism types 2 and 4. J Dermatol Sci. 2008;51(1):1–9.CrossRef
11.
go back to reference Wei A, Yang X, Lian S, Li W. Implementation of an optimized strategy for genetic testing of the Chinese patients with oculocutaneous albinism. J Dermatol Sci. 2011;62(2):124–7.CrossRef Wei A, Yang X, Lian S, Li W. Implementation of an optimized strategy for genetic testing of the Chinese patients with oculocutaneous albinism. J Dermatol Sci. 2011;62(2):124–7.CrossRef
12.
go back to reference Wei A-H, Zang D-J, Zhang Z, Liu X-Z, He X, Yang L, et al. Exome sequencing identifies SLC24A5 as a candidate gene for nonsyndromic oculocutaneous albinism. J Investig Dermatol. 2013;133(7):1834–40.CrossRef Wei A-H, Zang D-J, Zhang Z, Liu X-Z, He X, Yang L, et al. Exome sequencing identifies SLC24A5 as a candidate gene for nonsyndromic oculocutaneous albinism. J Investig Dermatol. 2013;133(7):1834–40.CrossRef
13.
go back to reference Spritz RA, Fukai K, Holmes SA, Luande J. Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet. 1995;56(6):1320–3.PubMedPubMedCentral Spritz RA, Fukai K, Holmes SA, Luande J. Frequent intragenic deletion of the P gene in Tanzanian patients with type II oculocutaneous albinism (OCA2). Am J Hum Genet. 1995;56(6):1320–3.PubMedPubMedCentral
14.
go back to reference Aquaron R, Soufir N, Bergé-Lefranc J-L, Badens C, Austerlitz F, Grandchamp B. Oculocutaneous albinism type 2 (OCA2) with homozygous 2.7-kb deletion of the P gene and sickle cell disease in a Cameroonian family. Identification of a common TAG haplotype in the mutated P gene. J Hum Genet. 2007;52(9):771–80.CrossRef Aquaron R, Soufir N, Bergé-Lefranc J-L, Badens C, Austerlitz F, Grandchamp B. Oculocutaneous albinism type 2 (OCA2) with homozygous 2.7-kb deletion of the P gene and sickle cell disease in a Cameroonian family. Identification of a common TAG haplotype in the mutated P gene. J Hum Genet. 2007;52(9):771–80.CrossRef
15.
go back to reference Cruz-Inigo AE, Ladizinski B, Sethi A. Albinism in Africa: stigma, slaughter and awareness campaigns. Dermatol Clin. 2011;29(1):79–87.CrossRef Cruz-Inigo AE, Ladizinski B, Sethi A. Albinism in Africa: stigma, slaughter and awareness campaigns. Dermatol Clin. 2011;29(1):79–87.CrossRef
16.
go back to reference Grønskov K, Dooley CM, Østergaard E, Kelsh RN, Hansen L, Levesque MP, et al. Mutations in c10orf11, a melanocyte-differentiation gene, cause autosomal-recessive albinism. Am J Hum Genet. 2013;92(3):415–21.CrossRef Grønskov K, Dooley CM, Østergaard E, Kelsh RN, Hansen L, Levesque MP, et al. Mutations in c10orf11, a melanocyte-differentiation gene, cause autosomal-recessive albinism. Am J Hum Genet. 2013;92(3):415–21.CrossRef
17.
go back to reference Mártinez-García M, Montoliu L. Albinism in Europe. J Dermatol. 2013;40(5):319–24.CrossRef Mártinez-García M, Montoliu L. Albinism in Europe. J Dermatol. 2013;40(5):319–24.CrossRef
18.
go back to reference Kutzbach BR, Merrill KS, Hogue KM, Downes SJ, Holleschau AM, MacDonald JT, Summers CG. Evaluation of vision-specific quality-of-life in albinism. J AAPOS. 2009;13(2):191–5.CrossRef Kutzbach BR, Merrill KS, Hogue KM, Downes SJ, Holleschau AM, MacDonald JT, Summers CG. Evaluation of vision-specific quality-of-life in albinism. J AAPOS. 2009;13(2):191–5.CrossRef
19.
go back to reference Chren MM, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9:97–100.CrossRef Chren MM, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004;9:97–100.CrossRef
20.
go back to reference Hay RJ, Fuller LC. Global burden of skin disease in the elderly: a grand challenge to skin health. G Ital Dermatol Venereol. 2015;150(6):693–8.PubMed Hay RJ, Fuller LC. Global burden of skin disease in the elderly: a grand challenge to skin health. G Ital Dermatol Venereol. 2015;150(6):693–8.PubMed
21.
go back to reference Boccara O, Méni C, Léauté-Labreze C, Bodemer C, Voisard J-J, Dufresne H, et al. Haemangioma family burden: creation of a specific questionnaire. Acta Derm Venereol. 2015;95(1):78–82.CrossRef Boccara O, Méni C, Léauté-Labreze C, Bodemer C, Voisard J-J, Dufresne H, et al. Haemangioma family burden: creation of a specific questionnaire. Acta Derm Venereol. 2015;95(1):78–82.CrossRef
22.
go back to reference Dufresne H, Hadj-Rabia S, Méni C, Sibaud V, Bodemer C, Taïeb C. Family burden in inherited ichthyosis: creation of a specific questionnaire. Orphanet J Rare Dis. 2013;8:28.CrossRef Dufresne H, Hadj-Rabia S, Méni C, Sibaud V, Bodemer C, Taïeb C. Family burden in inherited ichthyosis: creation of a specific questionnaire. Orphanet J Rare Dis. 2013;8:28.CrossRef
23.
go back to reference Taïeb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, et al. Atopic dermatitis burden scale for adults: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95(6):700–5.CrossRef Taïeb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, et al. Atopic dermatitis burden scale for adults: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95(6):700–5.CrossRef
24.
go back to reference Salzes C, Abadie S, Seneschal J, Whitton M, Meurant J-M, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136(1):52–8.CrossRef Salzes C, Abadie S, Seneschal J, Whitton M, Meurant J-M, Jouary T, et al. The vitiligo impact patient scale (VIPs): development and validation of a vitiligo burden assessment tool. J Invest Dermatol. 2016;136(1):52–8.CrossRef
25.
go back to reference Marquis P. Development and validation of a questionnaire: state of the art and level of evidence requiered. In: Marquis P, editor. Health-Related Quality Of Life And Patient Reported Outcomes: Scientific And Useful Outcome Criteria. London: Springer; 2002. p. 35–45. Marquis P. Development and validation of a questionnaire: state of the art and level of evidence requiered. In: Marquis P, editor. Health-Related Quality Of Life And Patient Reported Outcomes: Scientific And Useful Outcome Criteria. London: Springer; 2002. p. 35–45.
26.
go back to reference Acquadro C, Conway K, Hareendran A, Aaronson N. European regulatory issues and quality of life assessment (ERIQA) group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health. 2008;11:509–21.CrossRef Acquadro C, Conway K, Hareendran A, Aaronson N. European regulatory issues and quality of life assessment (ERIQA) group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. Value Health. 2008;11:509–21.CrossRef
27.
go back to reference Guyatt G, Jaeschke R. Measurements in clinical trials: choosing the appropriate approach. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press; 1990. p. 37–46. Guyatt G, Jaeschke R. Measurements in clinical trials: choosing the appropriate approach. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press; 1990. p. 37–46.
28.
go back to reference Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;6:167–88.CrossRef Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;6:167–88.CrossRef
29.
go back to reference Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107:238–46.CrossRef Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107:238–46.CrossRef
30.
go back to reference Lim LL, Fisher JD. Use of the 12-item short-form (SF-12) Health Survey in an Australian heart and stroke population. Qual Life Res. 1999;8:1–8.CrossRef Lim LL, Fisher JD. Use of the 12-item short-form (SF-12) Health Survey in an Australian heart and stroke population. Qual Life Res. 1999;8:1–8.CrossRef
31.
go back to reference Rosenberg M. Society and the Adolescent Self-Image. Rev ed. Middletown: Wesleyan University Press; 1989. Rosenberg M. Society and the Adolescent Self-Image. Rev ed. Middletown: Wesleyan University Press; 1989.
32.
go back to reference Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRef Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRef
33.
go back to reference Lewis V, Finlay AY. 10 years experience of the dermatology life questionnaire. J Investig Dermatol Symp Proc. 2004;9:169–80.CrossRef Lewis V, Finlay AY. 10 years experience of the dermatology life questionnaire. J Investig Dermatol Symp Proc. 2004;9:169–80.CrossRef
34.
go back to reference Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P, ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94–104.CrossRef Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P, ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94–104.CrossRef
35.
go back to reference Maria M, Volpini BMF, dos Santos GA, Rujula MJP. Quality of life in patients with oculocutaneous albinism. An Bras Dermatol. 2015;90(4):513–7.CrossRef Maria M, Volpini BMF, dos Santos GA, Rujula MJP. Quality of life in patients with oculocutaneous albinism. An Bras Dermatol. 2015;90(4):513–7.CrossRef
Metadata
Title
Burden of albinism: development and validation of a burden assessment tool
Authors
Fanny Morice-Picard
Charles Taïeb
Aurelie Marti
Antoine Gliksohn
Mohammed Bennani
Christine Bodemer
Khaled Ezzedine
Filière Maladies Rares en Dermatologie: FIMARAD
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0894-3

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue